Lumida
/LENZ
⌘K
LENZ Therapeutics Inc

LENZ Therapeutics Inc

LENZ
$5.18USD+6.15%+0.30 today

MARKET CAP

162.4M

P/E (TTM)

FWD P/E

DAY RANGE

$5 – $5

52W RANGE

$5
$50

AI Summary

Stalk
TrimMedium

LENZ is in a Stage 4 decline with persistent lower highs and lower lows under down-sloping EMAs, confirming bearish structure across both medium and long terms. Short-term execution timing is neutral as price tightly tracks below declining EMAs amid extreme oversold readings, offering no clear entry. With a speculative strategy requiring high selectivity, execution is deferred and best considered on any rally into EMA resistance.

  • Q1 revenue $1.9M from ~25K VIZ prescriptions, 19% QoQ growth
  • Telehealth prescribing option launched for direct home delivery access
  • Q1 net loss $41.5M exceeded revenue; SG&A set to total $80–100M
Full analysis →
Insider Trades9 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Mar 27, 2026BuyLENZDaniel R. ChevallardChief Financial Officer7,500$8.57$162.4M-89.72%+10.68%$64.3K+139.25%Trim
Mar 27, 2026BuyLENZEvert B. SchimmelpenninkPresident, CEO and Secretary28,089$8.95$162.4M-89.72%+10.68%$251.4K+57.09%Trim
Nov 17, 2025SellLENZShawn OlssonChief Commercial Officer20,000$14.09$162.4M-89.72%+10.68%$281.8K+0.00%10b5-1Trim
Nov 7, 2025BuyLENZDaniel R. ChevallardChief Financial Officer2,198$22.76$162.4M-89.72%+10.68%$50.0K+34.37%Trim
Apr 9, 2025BuyLENZShawn OlssonChief Commercial Officer1,400$2.08$162.4M-89.72%+10.68%$2.9K+2.10%Trim
Mar 7, 2025BuyLENZEvert B. SchimmelpenninkPresident, CEO and Secretary4,200$1.04$162.4M-89.72%+10.68%$4.4K+1.10%Trim
Dec 16, 2024BuyLENZShawn OlssonChief Commercial Officer3,333$2.08$162.4M-89.72%+10.68%$6.9K+5.16%Trim
Jul 22, 2024BuyLENZEvert B. SchimmelpenninkPresident, CEO and Secretary45,000$1.04$162.4M-89.72%+10.68%$46.8K+13.15%Trim
May 14, 2024BuyLENZDaniel R. ChevallardChief Financial Officer3,188$15.68$162.4M-89.72%+10.68%$50.0KTrim